CFTR-话题@MedSci

#CFTR#

13篇内容 | 1089人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1636453, encodeId=8e76163645338, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=ERJ-CFTR参与肺动脉高压的发病机制, objectType=article, longId=218395, objectId=b9b721839501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9b721839501, replyNumber=0, likeNumber=75, createdTime=2022-04-05, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9b721839501, moduleTitle=ERJ-CFTR参与肺动脉高压的发病机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9b721839501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636452, encodeId=0b2e1636452aa, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, objectType=article, longId=207122, objectId=8d1120e122ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d1120e122ef, replyNumber=0, likeNumber=79, createdTime=2021-11-24, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d1120e122ef, moduleTitle=Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d1120e122ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636451, encodeId=3a321636451bf, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, objectType=article, longId=201255, objectId=b45e20125596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b45e20125596, replyNumber=0, likeNumber=95, createdTime=2021-05-10, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b45e20125596, moduleTitle=FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45e20125596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636450, encodeId=4daa16364509e, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Clinica Chimica Acta：土耳其囊性纤维化患者CFTR基因突变和新变异？, objectType=article, longId=199107, objectId=df8b19910ed1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df8b19910ed1, replyNumber=0, likeNumber=65, createdTime=2020-11-12, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df8b19910ed1, moduleTitle=Clinica Chimica Acta：土耳其囊性纤维化患者CFTR基因突变和新变异？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df8b19910ed1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636449, encodeId=f68f16364495a, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=FDA批准Trikafta用于治疗CFTR基因突变的囊性纤维化患者, objectType=article, longId=181775, objectId=510f181e75bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=510f181e75bd, replyNumber=0, likeNumber=89, createdTime=2020-06-30, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=510f181e75bd, moduleTitle=FDA批准Trikafta用于治疗CFTR基因突变的囊性纤维化患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=510f181e75bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636448, encodeId=a1421636448b0, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Vertex公司的SYMDEKO获澳大利亚批准，用于治疗12岁以上CFTR基因突变的囊性纤维化患者, objectType=article, longId=162243, objectId=fc3a1622439e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3a1622439e, replyNumber=0, likeNumber=64, createdTime=2020-02-02, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3a1622439e, moduleTitle=Vertex公司的SYMDEKO获澳大利亚批准，用于治疗12岁以上CFTR基因突变的囊性纤维化患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3a1622439e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636447, encodeId=fc68163644edc, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化, objectType=article, longId=151869, objectId=2ac215186978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ac215186978, replyNumber=0, likeNumber=81, createdTime=2019-08-31, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ac215186978, moduleTitle=NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ac215186978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636446, encodeId=aef6163644650, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=CCLM：采用新一代测序技术进行CFTR基因扫描, objectType=article, longId=141329, objectId=088f141329ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=088f141329ea, replyNumber=0, likeNumber=103, createdTime=2018-07-26, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=088f141329ea, moduleTitle=CCLM：采用新一代测序技术进行CFTR基因扫描, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=088f141329ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636445, encodeId=b43e163644531, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, objectType=article, longId=101423, objectId=a07f101423fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a07f101423fa, replyNumber=0, likeNumber=73, createdTime=2018-03-09, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a07f101423fa, moduleTitle=Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a07f101423fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636444, encodeId=17ec1636444b4, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Cell：华人女科学家陈珏揭密囊性纤维化关键致病分子CFTR, objectType=article, longId=93721, objectId=2dad93e2158, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dad93e2158, replyNumber=0, likeNumber=74, createdTime=2017-05-30, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dad93e2158, moduleTitle=Cell：华人女科学家陈珏揭密囊性纤维化关键致病分子CFTR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dad93e2158)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636443, encodeId=38ac1636443eb, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Lancet：CFTR基因治疗对肺囊性纤维化有一定效果, objectType=article, longId=52872, objectId=4311528e29e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4311528e29e, replyNumber=0, likeNumber=61, createdTime=2016-03-20, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4311528e29e, moduleTitle=Lancet：CFTR基因治疗对肺囊性纤维化有一定效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4311528e29e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636442, encodeId=1614163644287, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=Nat Commun：研究证实CFTR蛋白参与调控胰岛素分泌, objectType=article, longId=38010, objectId=74e73801098, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74e73801098, replyNumber=0, likeNumber=0, createdTime=2015-05-23, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74e73801098, moduleTitle=Nat Commun：研究证实CFTR蛋白参与调控胰岛素分泌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74e73801098)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1636441, encodeId=60651636441eb, content=<a href='/topic/show?id=3dbd4532a9' target=_blank style='color:#2F92EE;'>#CFTR#</a>, objectTitle=VX-770在有囊性纤维化和G551D-CFTR突变者中的效果, objectType=article, longId=2234, objectId=b4a02234a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a02234a5, replyNumber=0, likeNumber=78, createdTime=2011-03-16, rootId=0, userName=644982816_68283328, userId=158922650058, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a02234a5, moduleTitle=VX-770在有囊性纤维化和G551D-CFTR突变者中的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a02234a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CFTR

2020-05-29

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

ERJ-CFTR参与肺动脉高压的发病机制

2022-04-05

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Lancet Respir Med：Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后

2021-11-24

医者仁心 (审核中...)

前往app查看评论内容

#CFTR#

FDA批准KALYDECO（ivacaftor）作为也是**的CFTR调节剂治疗囊性纤维化患儿

2021-05-10

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Clinica Chimica Acta：土耳其囊性纤维化患者CFTR基因突变和新变异？

2020-11-12

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

FDA批准Trikafta用于治疗CFTR基因突变的囊性纤维化患者

2020-06-30

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Vertex公司的SYMDEKO获澳大利亚批准，用于治疗12岁以上CFTR基因突变的囊性纤维化患者

2020-02-02

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

NEJM：VX-659-tezacaftor-ivacaftor三连疗法用于CFTR蛋白突变的囊性纤维化

2019-08-31

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

CCLM：采用新一代测序技术进行CFTR基因扫描

2018-07-26

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Lancet respir med：lumacaftor与依法卡托联合治疗对6-11岁携带F508del-CFTR纯合突变的肺囊性纤维化患者的疗效如何？

2018-03-09

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Cell：华人女科学家陈珏揭密囊性纤维化关键致病分子CFTR

2017-05-30

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Lancet：CFTR基因治疗对肺囊性纤维化有一定效果

2016-03-20

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

Nat Commun：研究证实CFTR蛋白参与调控胰岛素分泌

2015-05-23

644982816_68283328 (审核中...)

前往app查看评论内容

#CFTR#

VX-770在有囊性纤维化和G551D-CFTR突变者中的效果

2011-03-16

科室
- - 订阅+
  - 更多科室
工具
服务